person · Reporting owner

THERO JOHN F

Disclosed activity across 4 companies

Tapewire entity: 94414
SEC CIK: 0001199637

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cyteir Therapeutics, Inc.CYT · Entity 92707	Director	February 08, 2024	February 12, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cyteir Therapeutics, Inc.

Report date February 08, 2024 · Filed February 12, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	22,828	Reported balance After 2024-02-08 transaction · row 1 1 source row Row 1 · 2024-02-08 · Exercise / conversion · Acquired 12,828 · Balance 22,828
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03	Direct	0	Reported balance After 2024-02-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-08 · Exercise / conversion · Disposed 12,828 · Balance 0

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMARIN CORP PLC\UK

Report date July 30, 2021 · Filed August 04, 2021

Section 16 reporting ended · disclosed 2021-08-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	3,243,148	Reported balance After 2021-07-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-07-30 · Exercise / conversion · Acquired 6,736 · Balance 3,243,148 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable.
Ordinary SharesSEC Table I · non-derivative	Direct	3,249,884	Reported balance After 2021-07-30 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-07-30 · Exercise / conversion · Acquired 6,736 · Balance 3,249,884 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable.
Ordinary SharesSEC Table I · non-derivative	Direct	3,263,356	Reported balance After 2021-07-30 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2021-07-30 · Exercise / conversion · Acquired 13,472 · Balance 3,263,356 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable.
Ordinary SharesSEC Table I · non-derivative	Direct	3,252,752	Reported balance After 2021-07-30 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2021-07-30 · Tax withholding · Disposed 10,604 · Balance 3,252,752 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F5: Please see the section titled "Remarks" below for additional information.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	6,736	Reported balance After 2021-07-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-30 · Exercise / conversion · Disposed 6,736 · Balance 6,736 F6: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	6,736	Reported balance After 2021-07-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-30 · Exercise / conversion · Disposed 6,736 · Balance 6,736 F6: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	13,472	Reported balance After 2021-07-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-30 · Exercise / conversion · Disposed 13,472 · Balance 13,472 F6: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021.

F3: Not applicable.

F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.

F5: Please see the section titled "Remarks" below for additional information.

F6: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.

CHIASMA, INC

Report date August 05, 2021 · Filed August 05, 2021

Section 16 reporting ended · disclosed 2021-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.65	Direct	Reported balance After 2021-08-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-08-05 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.14	Direct	Reported balance After 2021-08-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-08-05 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35	Direct	Reported balance After 2021-08-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45	Direct	Reported balance After 2021-08-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.98	Direct	Reported balance After 2021-08-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81	Direct	Reported balance After 2021-08-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").

F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.

CinCor Pharma, Inc.

Report date February 24, 2023 · Filed February 24, 2023

Section 16 reporting ended · disclosed 2023-02-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2031-06-17	Direct	0	Reported balance After 2023-02-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-24 · Disposition to issuer · Disposed 36,324 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2031-12-09	Direct	0	Reported balance After 2023-02-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-02-24 · Disposition to issuer · Disposed 58,823 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 19, 2019 Filed Nov 22, 2019 01:49 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	274,454	$22.65	$6,217,371.13	Disclosure SEC source: 0001209191-19-057691 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,342,285 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2017 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.38 to $23.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 11, 2019 Filed Nov 14, 2019 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	41,741	$17.88	$746,295.69	Disclosure SEC source: 0001209191-19-056486 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,616,739 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2017 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $17.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 11, 2019 Filed Nov 14, 2019 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	433,805	$17.05	$7,397,156.10	Disclosure SEC source: 0001209191-19-056486 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,658,480 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2017 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.72 to $17.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
October 28, 2019 Filed Oct 31, 2019 00:10 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	11,601	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001209191-19-054568 · doc4.xml · derivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,400 Underlying: Ordinary Shares · 11,601 shares Expires 2025-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
October 28, 2019 Filed Oct 31, 2019 00:10 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	11,601	$2.50	$29,002.50	Disclosure SEC source: 0001209191-19-054568 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,092,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
October 07, 2019 Filed Oct 10, 2019 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	497,876	$14.37	$7,154,478.12	Disclosure SEC source: 0001209191-19-052866 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,080,684 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
October 07, 2019 Filed Oct 10, 2019 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantOrdinary Shares	1,265,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-052866 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,578,560 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: In January 2015, 2,530,500 restricted stock units (the "RSUs") were approved to be granted and, following the Annual General Meeting of Shareholders held in July 2015, were granted to the Reporting Person under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. The RSUs vested in two equal installments based on the Issuer's satisfaction of certain performance criteria and continued employment of the Reporting Person as provided in the Restricted Stock Unit Award Agreement between the Issuer and the Reporting Person. Vesting of the second and final installment was achieved based on a predetermined performance-based formula tied to company cash flow as determined by the Remuneration Committee of the Board of Directors, resulting in the vesting of 1,265,250 RSUs. F3 · price: Not applicable. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
August 21, 2019 Filed Aug 23, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	36,600	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001209191-19-047192 · doc4.xml · derivative · entry 6 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,400 Underlying: Ordinary Shares · 36,600 shares Expires 2025-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
August 21, 2019 Filed Aug 23, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	106,372	$0.00 Strike: $1.02	$0.00	Disclosure SEC source: 0001209191-19-047192 · doc4.xml · derivative · entry 5 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,628 Underlying: Ordinary Shares · 106,372 shares Expires 2025-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
August 21, 2019 Filed Aug 23, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	49,025	$0.00 Strike: $2.04	$0.00	Disclosure SEC source: 0001209191-19-047192 · doc4.xml · derivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,475 Underlying: Ordinary Shares · 49,025 shares Expires 2024-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
August 21, 2019 Filed Aug 23, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	36,600	$2.50	$91,500.00	Disclosure SEC source: 0001209191-19-047192 · doc4.xml · nonDerivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,324,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
August 21, 2019 Filed Aug 23, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	106,372	$1.02	$108,499.44	Disclosure SEC source: 0001209191-19-047192 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,288,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
August 21, 2019 Filed Aug 23, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	49,025	$2.04	$100,011.00	Disclosure SEC source: 0001209191-19-047192 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,181,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
August 21, 2019 Filed Aug 24, 2019 00:19 UTC Amendment	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	24,999	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001209191-19-047385 · doc4a.xml · derivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,001 Underlying: Ordinary Shares · 24,999 shares Expires 2025-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Due to an administrative error, the Form 4 filed by the Reporting Person on August 22, 2019 (the "Prior Form 4") included the wrong number of options that were exercised (36,600) and the wrong number of Ordinary Shares (2,324,911) and stock options of this class (563,400) beneficially owned following the reported transaction. This Form 4/A amends the Prior Form 4 to correct these figures. F4 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying_shares: Due to an administrative error, the Form 4 filed by the Reporting Person on August 22, 2019 (the "Prior Form 4") included the wrong number of options that were exercised (36,600) and the wrong number of Ordinary Shares (2,324,911) and stock options of this class (563,400) beneficially owned following the reported transaction. This Form 4/A amends the Prior Form 4 to correct these figures. F2 · balance_after: Due to an administrative error, the Form 4 filed by the Reporting Person on August 22, 2019 (the "Prior Form 4") included the wrong number of options that were exercised (36,600) and the wrong number of Ordinary Shares (2,324,911) and stock options of this class (563,400) beneficially owned following the reported transaction. This Form 4/A amends the Prior Form 4 to correct these figures. Read SEC document
August 21, 2019 Filed Aug 24, 2019 00:19 UTC Amendment	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	24,999	$2.50	$62,497.50	Disclosure SEC source: 0001209191-19-047385 · doc4a.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,313,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Due to an administrative error, the Form 4 filed by the Reporting Person on August 22, 2019 (the "Prior Form 4") included the wrong number of options that were exercised (36,600) and the wrong number of Ordinary Shares (2,324,911) and stock options of this class (563,400) beneficially owned following the reported transaction. This Form 4/A amends the Prior Form 4 to correct these figures. F2 · balance_after: Due to an administrative error, the Form 4 filed by the Reporting Person on August 22, 2019 (the "Prior Form 4") included the wrong number of options that were exercised (36,600) and the wrong number of Ordinary Shares (2,324,911) and stock options of this class (563,400) beneficially owned following the reported transaction. This Form 4/A amends the Prior Form 4 to correct these figures. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
June 30, 2019 Filed Jul 3, 2019 00:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	37,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-040574 · doc4.xml · derivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The sixteenth and final vesting event occurred on June 30, 2019. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 30, 2019 Filed Jul 3, 2019 00:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	14,757	$19.39	$286,138.23	Disclosure SEC source: 0001209191-19-040574 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,132,914 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
June 30, 2019 Filed Jul 3, 2019 00:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	37,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-040574 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,147,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The sixteenth and final vesting event occurred on June 30, 2019. F3 · price: Not applicable. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
June 13, 2019 Filed Jun 17, 2019 18:54 UTC	CHIASMA, INC CHMA · Entity 136487	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $7.98	$0.00	Disclosure SEC source: 0001209191-19-037508 · doc4.xml · derivative · entry 1 THERO JOHN F · CIK 0001199637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (1) June 13, 2020 and (ii) the date of the issuer's next annual meeting of the stockholders. Read SEC document
March 31, 2019 Filed Apr 2, 2019 00:24 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	37,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-022109 · doc4.xml · derivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Ordinary Shares · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The fifteenth vesting event occurred on March 31, 2019. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 31, 2019 Filed Apr 2, 2019 00:24 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	14,757	$20.76	$306,355.32	Disclosure SEC source: 0001209191-19-022109 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,110,171 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
March 31, 2019 Filed Apr 2, 2019 00:24 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	37,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-022109 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,124,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The fifteenth vesting event occurred on March 31, 2019. F3 · price: Not applicable. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	70,673	$21.70	$1,533,893.86	Disclosure SEC source: 0001209191-19-017568 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,087,428 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2017 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.47 to $22.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.direct: Please see the section titled "Remarks" below for additional information. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	179,327	$21.15	$3,793,339.90	Disclosure SEC source: 0001209191-19-017568 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,158,101 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2017 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.47 to $21.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.direct: Please see the section titled "Remarks" below for additional information. Read SEC document
February 01, 2019 Filed Feb 2, 2019 01:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (Right to Buy) · Derivative	302,500	$0.00 Strike: $16.88	$0.00	Disclosure SEC source: 0001209191-19-006640 · doc4.xml · derivative · entry 9 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,500 Underlying: Ordinary Shares · 302,500 shares Expires 2029-02-01 F11 · derivative.exercise_date: On February 1, 2019, the Reporting Person was granted an option to purchase 302,500 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 16 equal quarterly installments starting on May 15, 2019. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 01, 2019 Filed Feb 2, 2019 01:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	216,100	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-006640 · doc4.xml · derivative · entry 8 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,100 Underlying: Ordinary Shares · 216,100 shares Expires not disclosed F9 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F10 · derivative.exercise_date: On February 1, 2019, the Reporting Person was granted 216,100 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2020, January 31, 2021 and January 31, 2022. F4 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 31, 2019 Filed Feb 2, 2019 01:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	123,667	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-006640 · doc4.xml · derivative · entry 7 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,333 Underlying: Ordinary Shares · 123,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F7 · derivative.exercise_date: On February 1, 2018, the Reporting Person was granted 371,000 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2019, January 31, 2020 and January 31, 2021. The first vesting event occurred on January 31, 2019. F4 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 31, 2019 Filed Feb 2, 2019 01:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	119,667	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-006640 · doc4.xml · derivative · entry 6 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,666 Underlying: Ordinary Shares · 119,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F6 · derivative.exercise_date: On February 1, 2017, the Reporting Person was granted 359,000 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2018, January 31, 2019 and January 31, 2020. The second vesting event occurred on January 31, 2019. F4 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 31, 2019 Filed Feb 2, 2019 01:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	120,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-006640 · doc4.xml · derivative · entry 5 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 120,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F3 · derivative.exercise_date: On February 1, 2016, the Reporting Person was granted 360,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2017, January 31, 2018 and January 31, 2019. The third and final vesting event occurred on January 31, 2019. F4 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 31, 2019 Filed Feb 2, 2019 01:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	143,177	$16.94	$2,425,418.38	Disclosure SEC source: 0001209191-19-006640 · doc4.xml · nonDerivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,337,428 F1 · security: There are no market sales of securities reported on this Form 4. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F8 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F5 · ownership.direct: Please see the section titled "Remarks" below for additional information. Read SEC document
January 31, 2019 Filed Feb 2, 2019 01:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	123,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-006640 · doc4.xml · nonDerivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,480,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: There are no market sales of securities reported on this Form 4. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F7 · shares: On February 1, 2018, the Reporting Person was granted 371,000 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2019, January 31, 2020 and January 31, 2021. The first vesting event occurred on January 31, 2019. F4 · price: Not applicable. F5 · ownership.direct: Please see the section titled "Remarks" below for additional information. Read SEC document
January 31, 2019 Filed Feb 2, 2019 01:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	119,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-006640 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,356,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: There are no market sales of securities reported on this Form 4. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F6 · shares: On February 1, 2017, the Reporting Person was granted 359,000 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2018, January 31, 2019 and January 31, 2020. The second vesting event occurred on January 31, 2019. F4 · price: Not applicable. F5 · ownership.direct: Please see the section titled "Remarks" below for additional information. Read SEC document
January 31, 2019 Filed Feb 2, 2019 01:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	120,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-006640 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,237,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: There are no market sales of securities reported on this Form 4. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: On February 1, 2016, the Reporting Person was granted 360,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2017, January 31, 2018 and January 31, 2019. The third and final vesting event occurred on January 31, 2019. F4 · price: Not applicable. F5 · ownership.direct: Please see the section titled "Remarks" below for additional information. Read SEC document
December 31, 2018 Filed Jan 3, 2019 00:45 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	37,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-000513 · doc4.xml · derivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Ordinary Shares · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The fourteenth vesting event occurred on December 31, 2018. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
December 31, 2018 Filed Jan 3, 2019 00:45 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	14,757	$13.24	$195,382.68	Disclosure SEC source: 0001209191-19-000513 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,117,271 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
December 31, 2018 Filed Jan 3, 2019 00:45 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	37,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-000513 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,132,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The fourteenth vesting event occurred on December 31, 2018. F3 · price: Not applicable. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 12, 2018 Filed Nov 14, 2018 23:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	407,611	$0.00 Strike: $1.35	$0.00	Disclosure SEC source: 0001209191-18-058601 · doc4.xml · derivative · entry 6 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 407,611 shares Expires 2019-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: On December 21, 2009, the Reporting Person was granted an option to purchase 900,000 Ordinary Shares under the Amarin Corporation plc 2002 Stock Option Plan. The stock option is fully vested. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 12, 2018 Filed Nov 14, 2018 23:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	5,000	$20.72	$103,610.00	Disclosure SEC source: 0001209191-18-058601 · doc4.xml · nonDerivative · entry 5 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094,528 F1 · security: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person established in 2017. The option reported in this Form 4 was granted in 2009 and was set to expire in 2019. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.46 to $20.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 12, 2018 Filed Nov 14, 2018 23:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	222,158	$19.71	$4,378,645.32	Disclosure SEC source: 0001209191-18-058601 · doc4.xml · nonDerivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,099,528 F1 · security: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person established in 2017. The option reported in this Form 4 was granted in 2009 and was set to expire in 2019. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.43 to $20.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 12, 2018 Filed Nov 14, 2018 23:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	244,031	$19.03	$4,643,251.05	Disclosure SEC source: 0001209191-18-058601 · doc4.xml · nonDerivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,321,686 F1 · security: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person established in 2017. The option reported in this Form 4 was granted in 2009 and was set to expire in 2019. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.43 to $19.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 12, 2018 Filed Nov 14, 2018 23:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	136,422	$18.05	$2,462,389.82	Disclosure SEC source: 0001209191-18-058601 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,565,717 F1 · security: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person established in 2017. The option reported in this Form 4 was granted in 2009 and was set to expire in 2019. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.43 to $18.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 12, 2018 Filed Nov 14, 2018 23:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	407,611	$1.35	$550,274.85	Disclosure SEC source: 0001209191-18-058601 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,702,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person established in 2017. The option reported in this Form 4 was granted in 2009 and was set to expire in 2019. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
September 30, 2018 Filed Oct 2, 2018 23:11 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	37,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-053480 · doc4.xml · derivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Ordinary Shares · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The thirteenth vesting event occurred on September 30, 2018. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
September 30, 2018 Filed Oct 2, 2018 23:11 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	14,757	$16.27	$240,096.39	Disclosure SEC source: 0001209191-18-053480 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,294,528 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
September 30, 2018 Filed Oct 2, 2018 23:11 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	37,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-053480 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,309,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The thirteenth vesting event occurred on September 30, 2018. F3 · price: Not applicable. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
September 22, 2018 Filed Sep 25, 2018 22:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	497,876	$2.99	$1,488,649.24	Disclosure SEC source: 0001209191-18-052201 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,271,785 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F4 · ownership.direct: Please see the section titled "Remarks" below for additional information. Read SEC document
September 22, 2018 Filed Sep 25, 2018 22:35 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantOrdinary Shares	1,265,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052201 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,769,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: On February 2, 2015, the Reporting Person was granted 2,530,500 restricted stock units (the "RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. The RSUs vest in two equal installments based on the Issuer's satisfaction of certain performance criteria and continued employment of the Reporting Person as provided in the Restricted Stock Unit Award Agreement between the Issuer and the Reporting Person. The performance criteria for the first installment was met, resulting in vesting of 1,265,250 RSUs. F3 · price: Not applicable. F4 · ownership.direct: Please see the section titled "Remarks" below for additional information. Read SEC document
June 30, 2018 Filed Jul 3, 2018 20:11 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	37,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-040971 · doc4.xml · derivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The twelfth vesting event occurred on June 30, 2018. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 30, 2018 Filed Jul 3, 2018 20:11 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	14,757	$3.09	$45,599.13	Disclosure SEC source: 0001209191-18-040971 · doc4.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504,411 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
June 30, 2018 Filed Jul 3, 2018 20:11 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	37,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-040971 · doc4.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,519,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: As previously reported on July 8, 2015, the Reporting Person was granted 600,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The twelfth vesting event occurred on June 30, 2018. F3 · price: Not applicable. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.